Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Sep. 2025,
Fusion Antibodies received£0.57 Mil more from issuing new shares than it paid to buy back shares.
It spent£0.04 Mil paying down its debt.
It paid£0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received£0.00 Mil from paying cash dividends to shareholders.
It spent£0.01 Mil on other financial activities.
In all, Fusion Antibodiesearned£0.52 Mil on financial activities for the
six
months ended in Sep. 2025.
Fusion Antibodies (LSE:FAB) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Fusion Antibodies's issuance of stock for the
six
months ended in Sep. 2025 was £0.57 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Fusion Antibodies's repurchase of stock for the
six
months ended in Sep. 2025 was £0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Fusion Antibodies's net issuance of debt for the
six
months ended in Sep. 2025 was £-0.04 Mil.
Fusion Antibodies spent£0.04 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Fusion Antibodies's net issuance of preferred for the
six
months ended in Sep. 2025 was £0.00 Mil.
Fusion Antibodies paid£0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Fusion Antibodies's cash flow for dividends for the
six
months ended in Sep. 2025 was £0.00 Mil.
Fusion Antibodies received£0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Fusion Antibodies's other financing for the
six
months ended in Sep. 2025 was £-0.01 Mil.
Fusion Antibodies spent£0.01 Mil on other financial activities.
Fusion Antibodies Cash Flow from Financing Related Terms
Fusion Antibodies Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Fusion Antibodies's Cash from Financing for the fiscal year that ended in Mar. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £1.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of £1.06 Mil mean?
Fusion Antibodies (LSE:FAB) has a Cash Flow from Financing of £1.06 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Fusion Antibodies and its competitors.
Is Fusion Antibodies' Cash Flow from Financing too high?
Fusion Antibodies' current Cash Flow from Financing is £1.06 Mil.
How does Fusion Antibodies' Cash Flow from Financing compare to VRTX and REGN?
Fusion Antibodies' Cash Flow from Financing of £1.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Fusion Antibodies and its competitors. Fusion Antibodies's current Cash Flow from Financing is £1.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 162.5% above its estimated fair value. The current Cash Flow from Financing is £1.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Cash Flow from Financing is £1.06 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
